4D Molecular Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
4D Molecular Therapeutics, Inc. (FDMT) reported Increase (Decrease) in Prepaid Expense and Other Assets of $10.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $6.53M.
- 4D Molecular Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $3.99M, a 271.79% increase year-over-year.
- 4D Molecular Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $3.17M, a 165.74% increase year-over-year.
- 4D Molecular Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$2.75M.
- 4D Molecular Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $424.00K, a 75.04% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.70M, a 21.44% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.40M.
- 4D Molecular Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$1.24M, a 129.23% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $10.53M 10-Q · filed 2026-08-13 | $13.69M derived: sum of 3 quarters · filed 2026-08-13 | $10.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.99M 10-Q · filed 2026-05-07 | $7.16M derived: sum of 2 quarters · filed 2026-05-07 | $4.41M derived: sum of 3 quarters · filed 2026-05-07 | $3.34M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $417.00K derived: sum of 2 quarters · filed 2026-03-18 | -$650.00K derived: sum of 3 quarters · filed 2026-08-13 | $424.00K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$3.81M derived: sum of 2 quarters · filed 2026-08-13 | -$2.74M 10-Q · filed 2025-11-10 | -$1.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $7.00K 10-Q · filed 2026-08-13 | $1.20M derived: sum of 3 quarters · filed 2026-08-13 | -$624.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.07M 10-Q · filed 2026-05-07 | $2.27M derived: sum of 2 quarters · filed 2026-05-07 | $443.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.45M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$631.00K derived: sum of 2 quarters · filed 2026-03-18 | $377.00K derived: sum of 3 quarters · filed 2026-03-18 | $1.70M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$814.00K derived: sum of 2 quarters · filed 2025-11-10 | $508.00K 10-Q · filed 2025-11-10 | $285.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $2.33M 10-Q · filed 2025-08-11 | $2.11M derived: sum of 3 quarters · filed 2025-08-11 | $3.25M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.32M 10-Q · filed 2025-05-08 | $1.10M derived: sum of 2 quarters · filed 2025-05-08 | $2.25M derived: sum of 3 quarters · filed 2025-05-08 | $2.81M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $924.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.49M derived: sum of 3 quarters · filed 2025-02-28 | $1.40M 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.71M derived: sum of 2 quarters · filed 2024-11-13 | $1.62M 10-Q · filed 2024-11-13 | $4.08M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $565.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $475.00K 10-Q · filed 2024-08-08 | $2.93M derived: sum of 3 quarters · filed 2024-08-08 | $1.90M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$90.00K 10-Q · filed 2024-05-09 | $2.37M derived: sum of 2 quarters · filed 2024-05-09 | $1.33M derived: sum of 3 quarters · filed 2024-05-09 | -$308.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.43M derived: sum of 2 quarters · filed 2024-02-29 | -$218.00K derived: sum of 3 quarters · filed 2024-02-29 | -$1.24M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.68M derived: sum of 2 quarters · filed 2023-11-09 | -$3.69M 10-Q · filed 2023-11-09 | $1.71M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.66M 10-Q · filed 2023-08-09 | $2.74M derived: sum of 3 quarters · filed 2023-08-09 | $2.22M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.02M 10-Q · filed 2023-05-11 | $4.38M derived: sum of 2 quarters · filed 2023-05-11 | $3.86M derived: sum of 3 quarters · filed 2023-05-11 | $3.98M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $4.88M derived: sum of 2 quarters · filed 2023-03-15 | $5.00M derived: sum of 3 quarters · filed 2023-03-15 | $4.22M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$524.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$404.00K derived: sum of 2 quarters · filed 2022-11-08 | -$1.18M 10-Q · filed 2022-11-08 | $382.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$653.00K 10-Q · filed 2022-08-11 | $906.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.41M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$773.00K 10-Q · filed 2022-05-12 | $786.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.29M derived: sum of 3 quarters · filed 2022-05-12 | $1.94M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $2.06M derived: sum of 2 quarters · filed 2022-03-28 | $2.71M derived: sum of 3 quarters · filed 2022-03-28 | $2.57M 10-K · filed 2022-03-28 |
| 2020-09-30 | $504.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.15M derived: sum of 2 quarters · filed 2021-11-10 | $1.01M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $649.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $503.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$146.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $695.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |